These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22161852)

  • 1. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.
    Vilaine M; Olcaydu D; Harutyunyan A; Bergeman J; Tiab M; Ramée JF; Chen JM; Kralovics R; Hermouet S
    Blood; 2011 Dec; 118(24):6468-70. PubMed ID: 22161852
    [No Abstract]   [Full Text] [Related]  

  • 2. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
    Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
    Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
    [No Abstract]   [Full Text] [Related]  

  • 3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.
    Swierczek S; Nausova J; Jelinek J; Liu E; Roda P; Kucerova J; Jarosova M; Urbankova H; Indrak K; Prchal JT; Divoky V
    Am J Hematol; 2013 Feb; 88(2):157-8. PubMed ID: 23280542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.
    Wang L; Swierczek SI; Lanikova L; Kim SJ; Hickman K; Walker K; Wang K; Drummond J; Doddapaneni H; Reid JG; Muzny DM; Gibbs RA; Wheeler DA; Prchal JT
    Leukemia; 2014 Apr; 28(4):938-41. PubMed ID: 24463469
    [No Abstract]   [Full Text] [Related]  

  • 7. The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.
    Tagariello G; Di Gaetano R; Sartori R; Zanotto D; Belvini D; Radossi P; Risato R; Roveroni G; Salviato R; Tassinari C; Toffano N
    Blood Transfus; 2009 Apr; 7(2):111-6. PubMed ID: 19503632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
    Milosevic Feenstra JD; Jäger R; Schischlik F; Ivanov D; Eisenwort G; Rumi E; Schuster M; Gisslinger B; Machherndl-Spandl S; Bettelheim P; Krauth MT; Keil F; Bock C; Cazzola M; Gisslinger H; Kralovics R; Valent P
    Am J Hematol; 2022 Apr; 97(4):390-400. PubMed ID: 35015307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
    Tefferi A
    N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
    [No Abstract]   [Full Text] [Related]  

  • 10. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
    Grinfeld J; Godfrey AL
    Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
    Shi Y; Xu C
    Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
    J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
    Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
    Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
    Langabeer SE
    Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
    [No Abstract]   [Full Text] [Related]  

  • 18. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloproliferative neoplasms and JAK2 mutations.
    Almedal H; Vorland M; Aarsand AK; Grønningsæter IS; Bruserud Ø; Reikvam H
    Tidsskr Nor Laegeforen; 2016 Dec; 136(22):1889-1894. PubMed ID: 27929554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients.
    Reeves BN; Kim SJ; Song J; Wilson KJ; Henderson MW; Key NS; Pawlinski R; Prchal JT
    Am J Hematol; 2022 Feb; 97(2):E37-E40. PubMed ID: 34748652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.